RxDoctor Payments Data

Joel Torres, MD

Neuromuscular Medicine · Knoxville, TNNPI 1861751257

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $247 of the $294 with a category attached, or 84.1%. AstraZeneca accounts for 65.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $158 and has fallen 89.3% since, to $17 in 2023.

$294in general payments, 2019–2025

Across 9 payments — averaging $32.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$193
  • E.r. Squibb & Sons, L.L.C.$30
  • Kyowa Kirin, Inc.$17
  • AbbVie$17
  • EMD Serono, Inc.$13
  • Livanova USA, Inc.$13
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$24784%
  • Education$4716%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in Tennesseeto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$158,964
Medicare patients
441
Services billed
6,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4641$542,220
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5014$472,014
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5052$354,140
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5027$342,614
SolirisEculizumab12$314,679
GlatopaGlatiramer Acetate15$40,320
LamictalLamotrigine11$22,366
KeppraLevetiracetam11$13,106
Emgality PenGalcanezumab-Gnlm14$9,677
Pyridostigmine Bromide80$8,730
Gabapentin230$2,822
Mycophenolate Mofetil32$2,169
Duloxetine Hcl75$1,667
Carbidopa-LevodopaCarbidopa/Levodopa74$1,625
Riluzole21$1,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$193$314,67912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Tennesseeon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →